Cost-effectiveness analysis results.
| Cost | QALYs | Cost difference | QALY difference | ICER | |
| Base-case analysis | |||||
| ROCA price = £150 | |||||
| Control | £220 677 | 31.4291 | |||
| Surveillance | £202 337 | 31.6641 | -£18 340 | 0.179 | -£102 496 |
| Sensitivity analyses | |||||
| Impact of ROCA price | |||||
| Threshold analysis ROCA price = £585 | |||||
| Control | £220 677 | 31.4291 | |||
| Surveillance | £220 854 | 31.6641 | £177 | 0.179 | £987 |
| Impact of surveillance duration | |||||
| Surveillance stops at age 80 years | |||||
| Control | £220 677 | 31.4291 | |||
| Surveillance | £201 968 | 31.6069 | -£18 709 | 0.178 | -£104 854 |
| Surveillance stops at age 75 years | |||||
| Control | £220 677 | 31.4291 | |||
| Surveillance | £201 768 | 31.6069 | -£ 18 910 | 0.178 | -£106 326 |
| Surveillance stops at age 70 years | |||||
| Control | £220 677 | 31.4291 | |||
| Surveillance | £201 583 | 31.6059 | -£19 095 | 0.177 | -£107 951 |
| Surveillance stops at age 50 years | |||||
| Control | £220 677 | 31.4291 | |||
| Surveillance | £209 063 | 31.5759 | -£11 614 | 0.147 | -£79 086 |
| Impact of proportion of early-stage (stages 1 and 2) ovarian cancer detection in ALDO | |||||
| Probability of early cancer detection reduced by 10% from 33% base-case to 22% | |||||
| Control | £220 677 | 31.4291 | |||
| Surveillance | £210 797 | 31.5744 | -£9880 | 0.145 | -£67 976 |
| Probability of early cancer detection increased by 10% from 33% base-case to 43% | |||||
| Control | £220 677 | 31.4291 | |||
| Surveillance | £193 877 | 31.6416 | -£26 800 | 0.213 | -£126 106 |
| Probability of early cancer detection set at 11.5% (vs 33.3% at base-case) | |||||
| Control | £220 677 | 31.4291 | |||
| Surveillance | £220 780 | 31.5348 | £103 | 0.106 | £971 |
ALDO, Avoiding Late Diagnosis of Ovarian Cancer; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; ROCA, Risk of Ovarian Cancer Algorithm.